Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances
Jazyk angličtina Země Švédsko Médium print
Typ dokumentu časopisecké články
PubMed
30431741
PII: NEL390318A03
Knihovny.cz E-zdroje
- MeSH
- autoimunitní nemoci chemicky indukované MeSH
- dospělí MeSH
- humanizované monoklonální protilátky škodlivé účinky MeSH
- hydrokortison nedostatek MeSH
- hypofýza diagnostické zobrazování MeSH
- hypopituitarismus chemicky indukované diagnostické zobrazování MeSH
- ipilimumab škodlivé účinky MeSH
- kolitida chemicky indukované MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenitida chemicky indukované MeSH
- lymfocytární hypofyzitida chemicky indukované diagnostické zobrazování MeSH
- magnetická rezonanční tomografie MeSH
- melanom farmakoterapie patologie MeSH
- mezenterium MeSH
- nádory kůže farmakoterapie patologie MeSH
- pankreatitida chemicky indukované MeSH
- pneumonie chemicky indukované diagnostické zobrazování MeSH
- počítačová rentgenová tomografie MeSH
- protinádorové látky imunologicky aktivní škodlivé účinky MeSH
- retrospektivní studie MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- humanizované monoklonální protilátky MeSH
- hydrokortison MeSH
- ipilimumab MeSH
- pembrolizumab MeSH Prohlížeč
- protinádorové látky imunologicky aktivní MeSH
OBJECTIVES: Immune checkpoints inhibitors (ICI) represent a new therapy option for the treatment of several advanced tumors. However, this therapy has been linked to a spectrum of ICI related autoimmune (AI) adverse events. Some may be life threatening and their diagnosis is tricky. The aim of our study was to describe various imaging appearances of ICI related secondary hypophysitis and other coincidental AI diseases. MATERIAL AND METHODS: We included 28 patients (19 females, 9 men, mean aged 58±13 years), who were consecutively treated mostly for advanced stage melanoma by different ICI. All their CT/MRI records and clinical data were reviewed. RESULTS: We found 5 (18%) cases of endocrinology proven secondary hypophysitis; 2 cases of panhypopituitarism and 3 cases of central hypocortisolism. Four cases were MRI positive, 1 case was MRI negative. Three cases were accompanied by other AI diseases: 1 by hemorrhagic colitis and mesenterial lymphadenitis, 1 by AI pancreatitis and 1 by pneumonitis. On MRI pituitary gland was swollen in 3 cases, twice enhanced non-homogenously, once homogenously; infundibular enlargement was present in 2 cases. Those 3 cases reacted to glucocorticoid therapy by hypophyseal shrinkage. In 1 case of MRI positive hypophysitis, the pituitary gland was not enlarged, slightly nonhomogeneous with peripheral contour enhancement; no reaction to glucocorticoids was mentioned. CONCLUSION: Secondary hypophysitis is probably more common ICI related adverse event than reported in the literature. Its MRI appearance is variable. Most of our cases were in coincidence with other AI ICI related events that affected their clinical manifestations.